Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; this is a minor system-level update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedMinor site revision from v3.4.0 to v3.4.1 with no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision: v3.3.4 replaces the previous Revision: v3.3.3 on the page.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded New York and Oregon locations in the Locations section and updated the page revision to v3.3.3.SummaryDifference0.3%

- Check106 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; there are no changes to the study details, eligibility criteria, outcomes, or other user-facing content.SummaryDifference0.1%

Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.